How much has Genesis Therapeutics raised?

Genesis Therapeutics is best read as a venture-backed AI biotech with more than $300 million in compiled funding and separate pharma collaboration payments. Public funding databases and company releases do not always classify strategic upfronts, debt, and equity the same way, so this profile separates disclosed equity funding from business-development economics where relevant.

Key public backers include Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, and life-sciences investors. a16z is strategically important because it participated early and co-led the 2023 Series B through Bio + Health.

No current valuation has been announced. The valuation signal improved as Genesis moved from platform research toward internal programs and pharma collaborations, but there is no public mark to quantify that move.

Genesis has not disclosed profitability and is not an IPO candidate on public timelines. As a discovery-stage biotech platform, value creation is more likely tied to partner milestones, clinical progress, and pipeline optionality before any listing.

Treat Genesis as a scientific buyer with funding for mission-critical infrastructure. Strong pitches connect directly to drug-program throughput, model reliability, lab cycle time, security, and partner-reporting rigor.